Cite

HARVARD Citation

    Burt, R. et al. (2019). Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies. Human vaccines & immunotherapeutics. 15 (3), pp. 594-602. [Online]. 
  
Back to record